Abstract
12042 Background: Pneumonitis is one of the challenging adverse events in thoracic oncology patients undergoing cancer therapy. The cancer treatments, including targeted agents, systemic chemotherapy, immune-checkpoint inhibitors, and radiation therapy have recently advanced, however, the data on incidence of drug-induced and radiation pneumonitis (DP and RP) and their association with in-hospital outcomes is limited. Methods: Data from the National Inpatient Sample Database from 2016 to 2019 were analyzed. Adult patients with primary lung cancer were included and categorized into three groups: (1). Patients without pneumonitis, (2). Patients with DP, (3). Patients with RP. Outcomes included in-hospital mortality, intensive care unit (ICU) admission, and hospital length of stay (LOS). Data were extracted using ICD-10 codes. Results: Our analysis included 1,631,940 hospitalized primary lung cancer patients (based on a weighted sample). Among all, 4,515 patients had DP, and 16,905 patients had RP. Overall, 69.3% had smoking history, however, no significant difference between DP and RP. There was a higher prevalence of chronic obstructive pulmonary disease (COPD) in RP than DP (66.5% vs 53.2%; p<0.05) (Table). The in-hospital mortality rate was highest in DP compared to other groups. Coarsened exact matching method was used to balance covariates between non-pneumonitis and pneumonitis patients (DP and RP). Multivariate logistic regression showed that pneumonitis patients had higher odds of intubation (OR: 1.57; 95% CI: 1.24-1.99; p<0.05) and mortality (OR: 1.48; 95% CI: 1.28-1.71; p<0.05) than non-pneumonitis. Pneumonitis patients also had 23% longer length of stay than non-pneumonitis patients. We then compared the outcomes between DP and RP using the same matching algorithm, however, there was no significant difference in the outcomes between the two groups. Over the study years, the trend for DP significantly increased, whereas the RP trend was stable. Conclusions: Hospitalized pneumonitis patients had relatively poor clinical outcomes compared to patients without pneumonitis. The trend of hospitalized drug-induced pneumonitis is increasingly common. [Table: see text]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have